A clinical approach to the management of a patient with suspected renovascular disease who presents with leg ischemia
(2003) In International Angiology 22(4). p.333-339- Abstract
- Athernsclerotic renal artery stenosis (ARAS) may cause hypertension, progressive renal failure, and recurrent pulmonary edema. It typically occurs in high risk patients with coexistent vascular disease elsewhere. Most patients with ARAS are likely to die from coronary heart disease or stroke before end-stage renal failure occurs. Recent controlled trials have shown that most patients undergoing angioplasty to treat renovascular hypertension still need antihypertensive agents 6 or 12 months after the procedure. Nevertheless, the number of antihypertensive agents required to control blood pressure adequately is lower following angioplasty than for medication alone. Trials assessing the value of revascularization for preserving renal function... (More)
- Athernsclerotic renal artery stenosis (ARAS) may cause hypertension, progressive renal failure, and recurrent pulmonary edema. It typically occurs in high risk patients with coexistent vascular disease elsewhere. Most patients with ARAS are likely to die from coronary heart disease or stroke before end-stage renal failure occurs. Recent controlled trials have shown that most patients undergoing angioplasty to treat renovascular hypertension still need antihypertensive agents 6 or 12 months after the procedure. Nevertheless, the number of antihypertensive agents required to control blood pressure adequately is lower following angioplasty than for medication alone. Trials assessing the value of revascularization for preserving renal function or preventing clinical events are only in the early recruitment phase. Revascularization should be undertaken in patients with ARAS and resistant hypertension or heart failure, and probably in those with rapidly deteriorating renal function or with an increase in plasma creatinine levels during angiotensin-converting enzyme inhibition. With or without revascularization, medical therapy using antihypertensive, hypolipidemic and antiplatelet agents is necessary in almost all cases. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/283626
- author
- Plouin, PF ; Clement, DL ; Boccalon, H ; Dormandy, J ; Durand-Zaleski, I ; Fowkes, G ; Norgren, Lars LU and Brown, T
- organization
- publishing date
- 2003
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- peripheral vascular diseases, therapy, angioplasty, balloon, anti-hypertensive agents, risk factors, hypertension, renovascular
- in
- International Angiology
- volume
- 22
- issue
- 4
- pages
- 333 - 339
- publisher
- Minerva Medica
- external identifiers
-
- wos:000220430000001
- pmid:15153815
- scopus:1542621092
- ISSN
- 1827-1839
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Emergency medicine/Medicine/Surgery (013240200)
- id
- 69442d34-8c21-4a27-8036-b4e955432f99 (old id 283626)
- date added to LUP
- 2016-04-01 11:53:30
- date last changed
- 2022-01-26 19:48:15
@article{69442d34-8c21-4a27-8036-b4e955432f99,
abstract = {{Athernsclerotic renal artery stenosis (ARAS) may cause hypertension, progressive renal failure, and recurrent pulmonary edema. It typically occurs in high risk patients with coexistent vascular disease elsewhere. Most patients with ARAS are likely to die from coronary heart disease or stroke before end-stage renal failure occurs. Recent controlled trials have shown that most patients undergoing angioplasty to treat renovascular hypertension still need antihypertensive agents 6 or 12 months after the procedure. Nevertheless, the number of antihypertensive agents required to control blood pressure adequately is lower following angioplasty than for medication alone. Trials assessing the value of revascularization for preserving renal function or preventing clinical events are only in the early recruitment phase. Revascularization should be undertaken in patients with ARAS and resistant hypertension or heart failure, and probably in those with rapidly deteriorating renal function or with an increase in plasma creatinine levels during angiotensin-converting enzyme inhibition. With or without revascularization, medical therapy using antihypertensive, hypolipidemic and antiplatelet agents is necessary in almost all cases.}},
author = {{Plouin, PF and Clement, DL and Boccalon, H and Dormandy, J and Durand-Zaleski, I and Fowkes, G and Norgren, Lars and Brown, T}},
issn = {{1827-1839}},
keywords = {{peripheral vascular diseases; therapy; angioplasty; balloon; anti-hypertensive agents; risk factors; hypertension; renovascular}},
language = {{eng}},
number = {{4}},
pages = {{333--339}},
publisher = {{Minerva Medica}},
series = {{International Angiology}},
title = {{A clinical approach to the management of a patient with suspected renovascular disease who presents with leg ischemia}},
volume = {{22}},
year = {{2003}},
}